Incyte axes JAK1 inhibitor from pipeline two years after a PhIII flop crushed hopes
In the first few days of 2020, Incyte reported that its JAK1 inhibitor failed a Phase III study in first-line, acute graft vs host disease. With the flop came a $2 billion market cap erasure.
This time around, Incyte isn’t even completing a study of the drug, known as itacitinib, because efficacy data from part of a Phase II/III study give the biopharma no signs of hope for a pivotal success.
The GRAVITAS-309 study was testing itacitinib in patients with treatment-naïve chronic GVHD, but the company decided to scrap those plans, it revealed Tuesday in a quarterly earnings update.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,300+ biopharma pros reading Endpoints daily — and it's free.